Balyasny Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-56,362
| Closed | -$84.5K | – | 2106 |
|
|
2023
Q1 | $84.5K | Buy |
56,362
+32,622
| +137% | +$48.9K | ﹤0.01% | 1896 |
|
|
2022
Q4 | $27.8K | Buy |
+23,740
| New | +$27.8K | ﹤0.01% | 1998 |
|
|
2022
Q3 | – | Sell |
-10,432
| Closed | -$16K | – | 2571 |
|
|
2022
Q2 | $16K | Buy |
+10,432
| New | +$16K | ﹤0.01% | 2062 |
|
|
2021
Q2 | – | Sell |
-36,162
| Closed | -$85K | – | 1882 |
|
|
2021
Q1 | $85K | Buy |
+36,162
| New | +$85K | ﹤0.01% | 1463 |
|
|
2018
Q2 | – | Sell |
-34,416
| Closed | -$81K | – | 1776 |
|
|
2018
Q1 | $81K | Buy |
+34,416
| New | +$81K | ﹤0.01% | 1651 |
|
|
2015
Q4 | – | Sell |
-12,700
| Closed | -$31K | – | 1194 |
|
|
2015
Q3 | $31K | Hold |
12,700
| – | – | ﹤0.01% | 937 |
|
|
2015
Q2 | $37K | Buy |
+12,700
| New | +$37K | ﹤0.01% | 878 |
|